(Reuters) – Moderna Inc and Johnson & Johnson said on Tuesday that US regulators should authorize booster doses of their Covid-19 vaccines, citing data that showed both diminishing effectiveness over time.
The comments were released in briefing documents by the companies ahead of a meeting of external FDA expert advisors on Thursday and Friday to discuss booster doses of the vaccines.
Moderna cited data supporting the public health benefit of a booster dose and advocated a US authorization for the injection in adults 65 years of age and older and high-risk individuals.
The Pfizer/BioNTech vaccine is currently offered as a booster dose in the United States and is available to people 65 years of age and older, as well as those who are at high risk of serious illness or are regularly exposed to the virus.
Johnson & Johnson on Tuesday highlighted the benefits of a booster dose and said its data suggest the additional injection could benefit high-risk individuals if given two months after the original dose and after six months for low-risk Americans. risk.
The meeting will assess Moderna’s booster dose on Thursday, followed by a discussion around J&J’s booster dose on Friday.
(Reporting by Manas Mishra in Bengaluru)
+ Until 2019, there were more people in prisons than on the Brazilian stock exchange
+ Aloe gel in the drink: see the benefits
+ Lemon-squeezing trick becomes a craze on social media
+ Chef playmate creates aphrodisiac recipe for Orgasm Day
+ Mercedes-Benz Sprinter wins motorhome version
+ Anorexia, an eating disorder that can lead to death
+ US agency warns: never wash raw chicken meat
+ Yasmin Brunet breaks the silence
+ Shark is captured in MA with the remains of youngsters missing in the stomach
+ See how much it costs to eat at the MasterChef judges’ restaurants
+ Auction of cars and motorcycles from Kombi to Nissan Frontier 0km